However, clinical studies have reported controversial results regarding the significance of the tumor-infiltrating CD8<sup>+</sup> T-cells/PD-L1 axis on the clinical picture and the response rate of patients with high-grade glial tumors to anti-cancer therapies. The gene discussed is CD274; the disease is neoplasm.